Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics Inc (NQ: FLGT )

39.80 +0.46 (+1.18%)
Streaming Delayed Price Updated: 12:58 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulgent Genetics Inc

< Previous 1 2 3 4 5 6 7 Next >
2 Stocks That Are More Likely to Double Your Money Than Dogecoin
Wall Street is nervous, but these companies see growth beyond the pandemic. 
Via The Motley Fool
From Short Squeezes To Silver
Updates on our two recent heavily-shorted top names; a shift to silver. 
Via Talk Markets
What Does Life After COVID Look Like for Fulgent Genetics?
Fulgent rode on a wave of COVID revenue. What comes next could be pretty special. 
Via The Motley Fool
AMC Goes Parabolic: Looking For The Next Short Squeeze Candidate.
Moviegoers at an AMC theater waiting for a showing of the last Fast & Furious movie (photo via author). Crypto Crabs While AMC Skyrockets A point we made last week... 
Via Benzinga
AMC Goes Parabolic
Our top name from April was up 568% as of Wednesday's close. Looking for the next short squeeze candidate. 
Via Talk Markets
8 Stocks With The Highest Short Percent Of Float Right Now
Traders often look at short interest to get a sense of how many people are bearish on a stock and how strong the possibility of a short squeeze is. But simply looking at the size... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Step Aside AMC: Here Are The Most Shorted Stocks Right Now
Just like in late January the common theme here is that all these stocks are extremely heavily shorted, and retail investors are seeking to squeeze the shorts once again and this time with even more... 
Via Talk Markets
How Long Will Fulgent Genetics Benefit From the Pandemic?
Genetic testing for the coronavirus is slowing. 
Via The Motley Fool
Exposures COVID-19
Forget Dogecoin -- Buy These 3 Growth Stocks Instead
They are all coming off some impressive quarterly results. 
Via The Motley Fool
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Week In Review: GenScript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
GenScript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to GenScript's Legend Biotech CAR-T subsidiary. Before the... 
Via Talk Markets
What Are Investors Thinking About Fulgent Genetics?
Hint: It has something to do with COVID-19. 
Via The Motley Fool
Fulgent Genetics Announces Incremental Strategic Investment in Chinese Joint Venture, FF Gene Biotech
From Fulgent Genetics, Inc.
Via Business Wire
Why Investors Loved Fulgent Genetics' Q1 Results
More than 4,500% revenue growth gave Wall Street and shareholders something to cheer about. 
Via The Motley Fool
Fulgent Genetics, Inc. Common Stock (FLGT) Q1 2021 Earnings Call Transcript
FLGT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers T2 Biosystems (NASDAQ:TTOO) share... 
Via Benzinga
Fulgent Genetics Reports Record First Quarter Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Welcomes Dr. Lawrence Weiss as Chief Medical Officer
From Fulgent Genetics, Inc.
Via Business Wire
Why Shares of Fulgent Genetics Fell 20% in April
Good news for the U.S. has been bad news for shareholders. 
Via The Motley Fool
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
2 Numbers That Explain How This Hypergrowth Company Can Make You Rich
The genetic testing giant's journey resembles the path of past winners. 
Via The Motley Fool
3 Healthcare Stocks About to be Bolstered by Biden's American Rescue Plan
The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit. 
Via The Motley Fool
Exposures COVID-19
2 Unsustainable Growth Stocks to Avoid
Be wary of companies posting abnormal growth rates. 
Via The Motley Fool
Fulgent Genetics' CEO Just Told Investors To Look Out For An Acquisition
He also gave clues that point to a few possible targets. 
Via The Motley Fool
1 Number That Should Shock Fulgent Genetics Investors
Growth last year was awesome, but there is something to be even more excited about. 
Via The Motley Fool
Exposures COVID-19
Got $5,000? These 2 Ultra-Cheap Stocks Are Bargain Buys
They've underperformed the S&P 500 in the past month, but these stocks show lots of potential over the long term. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.